Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Obinutuzumab in Relapsed/Refractory Primary CNS Lymphoma
NCT04073147Phase 1Terminated
- Sponsor
- Klinikum Stuttgart
- Start
- May 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax in primary central nervous system lymphoma (PCNSL) (3 arms), sponsored by Klinikum Stuttgart. Primary endpoint: Pharmacokinetics of venetoclax and obinutuzumab at Day 28. Started May 2020; status: terminated.
02
Drugs
venetoclax
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04073147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073147.